Genentech Inc. South San Francisco, said its...
- Share via
Genentech Inc. South San Francisco, said its foreign licensee, Boehringer Ingelheim International GmbH, has received approval to market T-PA in France for the treatment of heart patients. T-PA is a human protein that dissolves blood clots that cause heart attacks.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
